Iron chelation therapy for myelodysplastic syndrome: a systematic review and meta-analysis

Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a syste...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental medicine 2020-02, Vol.20 (1), p.1-9
Hauptverfasser:	Liu, Hailing, Yang, Nan, Meng, Shan, Zhang, Yang, Zhang, Hui, Zhang, Wanggang
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood transfusion Chelation Chelation Therapy - methods Health risk assessment Hematology Humans Internal Medicine Iron Iron Overload - drug therapy Iron Overload - etiology Medicine Medicine & Public Health Meta-analysis Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - complications Myelodysplastic Syndromes - metabolism Oncology Review Article Survival Survival Analysis Systematic review Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Iron overload remains a concern in myelodysplastic syndrome (MDS) patients especially those requiring recurrent blood transfusions. Whether iron chelating therapy (ICT) is beneficial to the long-term survival of myelodysplastic syndrome is still a controversial issue. Therefore, we conducted a systematic review and meta-analysis to clarify the relationship between ICT and long-term survival in patients with MDS. A total of 14 studies involving 7242 participants were identified; the outcomes revealed that for patients with MDS, ICT resulted in a lower risk of mortality compared to those with no ICT (HR 0.57; 95% CI 0.44–0.70; P
ISSN:	1591-8890 1591-9528
DOI:	10.1007/s10238-019-00592-5